F S&P 500
5,540.75 +19.25 (+0.35%) F Dow Jones
39,559.00 +90.00 (+0.23%) F Nasdaq
20,018.00 +90.75 (+0.46%) E-mini Russell 2000 Index Futur
2,076.50 +11.50 (+0.56%) Petróleo
82.06 +0.52 (+0.64%) Oro
2,336.90 -2.70 (-0.12%)
Scancell Holdings plc (SCNLF)
Scancell Holdings plc
Bellhouse Building
Unit 202 Sanders Road Oxford Science Park
Oxford OX4 4GD
United Kingdom
44 18 6558 2066
https://www.scancell.co.uk
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 51
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Prof. Lindy Gillian Durrant Ph.D. | Founder, CEO, Chief Scientific Officer & Director | 466.87k | N/D | 1957 |
| Dr. Sally Elizabeth Adams | Executive Officer | 320.63k | N/D | 1961 |
| Mr. Sathijeevan Nirmalananthan | CFO, Company Secretary & Director | N/D | N/D | 1986 |
| Dr. Samantha Paston Ph.D. | Head of Translational Research | N/D | N/D | N/D |
| Dr. Adrian Parry Ph.D. | Head of Manufacturing | N/D | N/D | N/D |
| Dr. Mandeep Sehmi | Head of Business Development | N/D | N/D | N/D |
| Dr. Callum Scotthasbeen | Head of Development | N/D | N/D | N/D |
| Mr. Alex Hayward | Head of Finance | N/D | N/D | N/D |
Descripción
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, ovarian, renal, and head and neck cancers; and Modi-2, which targets homocitrullinated cancer antigens. In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Gestión corporativa
La calificación ISS Governance QuickScore de Scancell Holdings plc a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
